Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

alpha galactosidase/diarrea

L'enllaç es desa al porta-retalls
Pàgina 1 des de 19 resultats

The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Bloating, abdominal distention, and flatulence represent very frequent complaints in functional disorders but their pathophysiology and treatment are largely unknown. Patients frequently associate these symptoms with excessive intestinal gas and the reduction of gas production may represent an

Prevalence of Serpulina species in relation to diarrhea and feed medication in pig-rearing herds in Sweden.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE To determine prevalence of various pheno- and genotypes of Serpulina sp in young pigs in relation to diarrhea and feed medication in Swedish pig-rearing herds. METHODS Isolation of spirochetes. Phenotypical and genotypical classification. METHODS Young pigs (n = 358) in 19 pigrearing

Does oral α-galactosidase relieve irritable bowel symptoms?

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE Abdominal bloating is reported by a majority of irritable bowel syndrome (IBS) patients. Excess colonic fermentation may cause gaseous symptoms. Several foodstuffs contain oligosaccharides with an α-galactosidic linkage that is resistant to mammalian hydrolases. Assisted hydrolysis by
Frequent incidence of Serpulina strains showing all cultural and biochemical characteristics of Serpulina (S.) hyodysenteriae except of being indole negative, and alpha-galactosidase positive isolates showing strong haemolysis on Columbia agar with 5% sheep blood and trypticase soy agar with 5% ox

Fabry disease: case report with emphasis on enzyme replacement therapy and possible future therapeutic options.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
A 38-year-old male Caucasian with Fabry disease presented with angiokeratomas and tortuous conjunctival and retinal vessels. Additionally, the patient showed characteristic skin lesions of psoriasis and seborrheic dermatitis. His past medical history revealed anhidrosis, acral paresthesias,

Fabry disease simulating Crohn's ileitis.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Fabry disease is an inherited (X-linked) lysosomal storage disorder caused by deficiency of α-galactosidase A, leading to accumulation of globotriaosylceramide in various tissues. A 57-year-old male with a family history and laboratory findings of Fabry disease, was consulted for severe abdominal
Fabry disease (FD) is an X-linked lysosomal disorder caused by mutations in GLA gene resulting in lack of or faulty α-galactosidase A (α-GalA) enzyme. Enzyme replacement therapy (ERT) with recombinant human α-GalA enzyme (agalsidase) is the standard treatment option for FD. Infusion-related

Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Gastrointestinal symptoms are often an early and prominent manifestation of Fabry disease, an X-linked inborn error of metabolism caused by the deficient activity of the lysosomal enzyme, alpha-galactosidase A. This enzyme deficiency results in the progressive accumulation of globotriaosylceramide

[Fabry's disease and hypoparathyroidism].

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND Fabry's disease is due to alpha-galactosidase deficiency. This rare lysosomal storage disease is transmitted by recessive X-linked heredity. Sphingolipids (galactosyl-glucosyl-ceramide) accumulate in many organs. METHODS A 19-year-old man with known hypoparathyroidism presented with

Fabry disease: treatment and diagnosis.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Fabry disease is an X-linked lysosomal disorder that results from a deficiency of the lysosomal enzyme alpha-galactosidase A leading to accumulation of glycolipids, mainly globotriaosylceramide in the cells from different tissues. Classical Fabry disease affects various organs. Clinical

Classification of Brachyspira spp. isolated from Swedish dogs.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Brachyspira spp. were isolated from 21 of 32 sampled dogs (66%) in a colony of Swedish beagle dogs with a history of diarrhea and from 3 of 17 Swedish pet dogs (17%) with diarrhea. All Swedish isolates were weakly beta-hemolytic and gave a negative indole reaction. Eighty-eight percent showed

[Clinical courses of two male siblings on hemodialysis for Fabry disease ].

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Fabry disease is an X-linked recessive disease resulting from a deficiency of the lysosomal hydrolase alpha-galactosidase A. In male patients with the classic hemizygous form, acroparesthesias, hypohidrosis, corneal opacities, and dysfunction of the heart, brain, and kidney are observed. Recently,

Oxidative Stress and Cardiovascular-Renal Damage in Fabry Disease: Is There Room for a Pathophysiological Involvement?

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Fabry disease is an X-linked lysosomal storage disease caused by mutations in the GLA gene that lead to a reduction or an absence of the enzyme α-galactosidase A, resulting in the progressive and multisystemic accumulation of globotriaosylceramide. Clinical manifestation varies from mild to severe,
Outcomes in patients with Fabry disease receiving migalastat during the phase 3 FACETS trial (NCT00925301) were evaluated by phenotype.

METHODS
Data were evaluated in two subgroups of patients with migalastat-amenable GLA variants: "classic

Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND Fabry's disease, an X-linked disorder of lysosomal α-galactosidase deficiency, leads to substrate accumulation in multiple organs. Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms of α-galactosidase, increasing enzyme trafficking to lysosomes. METHODS The
Uneix-te a la nostra
pàgina de Facebook

La base de dades d’herbes medicinals més completa avalada per la ciència

  • Funciona en 55 idiomes
  • Cures a base d'herbes recolzades per la ciència
  • Reconeixement d’herbes per imatge
  • Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
  • Llegiu publicacions científiques relacionades amb la vostra cerca
  • Cerqueu herbes medicinals pels seus efectes
  • Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents

Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades

Google Play badgeApp Store badge